S&P 500 7718.60 -0.38%
NASDAQ 26506.99 -0.29%
TASI 11024.73 -0.40%
Oil (WTI) 91.48 +0.00%
Oil (Brent) 96.28 +0.00%
VIX 15.30 +5.30%
Gold 4476.60 +0.00%
USD/SAR 3.76 +0.02%

Amgen Inc.

AMGN · Healthcare · · USD
437.23 USD
0.00 (-1.55%)
● Updated 2026-09-07 19:34 Saudi Time ↻ Refresh
Short-term Mid-term Long-term

Fahodi Score HOLD Long-term (Investment)

63
/ 100
Technical 75
Trend & RS 96
Momentum 82
Fundamental 56
Macro 64
Liquidity 51
ComponentScoreWeight
Technical 75.0 10%
Trend & RS 96.0 10%
Momentum 81.5 5%
Fundamental 55.6 40%
Macro 64.4 15%
Liquidity 51.1 20%

Trade Setup

Entry 437.23
Stop Loss 418.17 (4.4%)
Target 1 (1:1) 456.29 (+4.4%)
Target 2 (2:1) 475.35 (+8.7%)
ATR(14) 9.53 (2.2%)
Risk per Share 19.06
Reward:Risk 2:1

ATR-based levels. Adjust for support/resistance zones.

Factor Profile

Factor Score Z Bar
Value 25.4 -0.99
Momentum 81.5 +1.26
Quality 63.6 +0.54
Composite 56.8

Quality Scores

Piotroski F-Score 5 /9 — Average
✓ ✓ ✗ ✗ ✗ ✗ ✓ ✓ ✓
1. Positive Net Income 2. Positive Roa 3. Positive Cfo 4. Quality Earnings 5. Lower Leverage 6. Higher Liquidity 7. No Dilution 8. Higher Gross Margin 9. Higher Asset Turnover
Altman Z-Score Insufficient Data

Valuation vs Peers Overvalued

MetricStockSectorvs Peers
P/E Ratio 27.2 22.0 +24% above
P/B Ratio 20.2 4.0 Above
Dividend Yield 2.3% 1.5% Above avg

Comparing against Healthcare median multiples.

Trading at a premium to sector peers — verify growth justifies premium.

Intrinsic Value (DCF) Significantly Overvalued

Intrinsic Value
272.93
vs
Market Price
437.23
Upside
-37.6%
Margin of Safety -60.2%
Stage 1 PV (5yr FCF)35,276,846,676
Terminal Value PV112,278,449,788
Total Enterprise Value147,555,296,464

Assumptions

Base FCF6,959,015,324
Growth Rate (5yr)9.5%
Terminal Growth2.5%
Discount Rate (WACC)9.0%

2-stage DCF: 5yr projected FCF + Gordon Growth terminal value. Estimates only — adjust growth and WACC for your own assumptions.

Position Sizing — Kelly Criterion

4.5%
Recommended Size
41.58%
Full Kelly
20.79%
Half Kelly
5.0%
Max Cap (Moderate)

Kelly inputs derived from quant score 63/100. Estimated win rate 59%, avg win 8.8%, avg loss 3.7%. Position was capped at the moderate risk maximum. This is analytical output, not a recommendation to trade.

BEAR Regime: BEAR (20% confidence) — position size reduced 10%

Signal Summary STRONG BUY

3
Bullish Signals
1
Bearish Signals
62.51
RSI(14)
13.3558
MACD

Relative Strength (RS) IMPROVING

89
/ 99
RS Rating
✓ O'Neil PASS (≥80)
RS vs SPY ↑ RISING (+21.1% vs SPY 3M)
RS vs Sector OUTPERFORMING (Healthcare)
RS New High No (9d since high)
Sector Outperformance +18.0% (3M)
RS Line — stock / SPY (90 bars)
← older newer →
RS vs SPY 50-day SMA of RS
IMPROVING: Gaining momentum — the stock is starting to outperform the market. Watch for RS new high confirmation.

Technical Indicators

IndicatorValueSignal
Rsi 62.51 NEUTRAL
Macd 13.3558 BEARISH
Ma Cross 395.32 / 354.22 GOLDEN CROSS
Trend Short ABOVE SMA50
Trend Long ABOVE SMA200
Bollinger MIDDLE
Volume 0.74x NORMAL

Key Levels

LevelPrice
52-Week High447.03
Bollinger Upper454.27
SMA(200)354.22
SMA(50)395.32
SMA(20)430.34
Current Price437.23
Bollinger Lower406.4
52-Week Low269.77
ATR(14)9.53

Advanced Technical Analysis

Click to expand

Wyckoff Phase & Volume Spread Analysis

Wyckoff Phase

MARKUP Confidence
100%
Acc: 0.0  |  Dist: 0.0  |  Markup: 2.0  |  Markdown: 0.0

Volume Spread Analysis (last 5 bars)

DateSignalVolDescription
2026-08-31 Normal 1.05x Normal bar — no special VSA pattern
2026-09-01 Normal 1.05x Normal bar — no special VSA pattern
2026-09-02 Normal 1.02x Normal bar — no special VSA pattern
2026-09-03 Normal 0.82x Normal bar — no special VSA pattern
2026-09-04 Normal 0.74x Normal bar — no special VSA pattern

Ichimoku Cloud BULLISH

LineValueStatus
Tenkan-sen (9) 436.51 Above Kijun
Kijun-sen (26) 410.40 Base line
Senkou A 423.46 Leading span A
Senkou B 395.51 Leading span B
Cloud 395.51 – 423.46 Bullish (Green)
Price vs Cloud 437.23 Above Cloud
Chikou Span 382.92 Bullish
Alignment Score 4/4 BULLISH

TTM Squeeze & Divergences

TTM Squeeze

SQUEEZE OFF No squeeze Momentum: BULLISH FADING
BB: 406.4 – 454.27  |  KC: 416.82 – 443.86

Divergences (last 60 bars)

No significant divergences detected in the last 60 bars.

Anchored VWAP

VWAP: 344.15 Anchor: 2025-09-26 (52w Low) ABOVE AVWAP +27.1%

Heikin-Ashi Trend

WEAKLY BEARISH Full data via /api/advanced/AMGN

Valuation

MetricValue
Market Cap236.38B
P/E (TTM)27.17
Forward P/EN/A
P/B20.22
EPS16.09

Financial Health

MetricValue
Revenue Growth9.5%
Profit Margin23.0%
ROE91.5%
Debt/Equity490.28
Current Ratio1.37
Dividend Yield2.3%
Payout RatioN/A
Beta0.43

Trading Data

437.23
Open
437.23
Day High
437.23
Day Low
1.66M
Volume (0.6x avg)

Recent News (8)

IBB Just Beat the S&P 500 by 22 Points in Three Months. Are You Late to the Party?
24/7 Wall St. · 2026-09-07
Amgen Shares Fall as Novartis' Pelacarsen Misses Phase III Study Goal
Zacks · 2026-09-07
Here's How Trump's Drug Deals Are Likely to Impact Healthcare ETFs
Zacks · 2026-09-07
A Novartis Heart Drug Trial Stumbles. Can a Rare-Disease Treatment Lift Shares?
Barrons.com · 2026-09-05
NVS, IONS, AMGN Stocks Drop After-Hours — What’s Driving The Selloff?
Stocktwits · 2026-09-04
Revolution Medicines Got Its Breakthrough—What Moves It Next?
MarketBeat · 2026-09-04
Amgen (AMGN) Says Repatha Reduced Mortality Before a First Heart Attack or Stroke. Can Earlier Use Expand the Market?
Insider Monkey · 2026-09-04
AMGN's MariTide: Can Convenience Drive its Obesity Market Share?
Zacks · 2026-09-04

Price Chart (90 Days)

Candlesticks (green=up, red=down) SMA 20 SMA 50 Bollinger Bands (upper/lower) Volume (green=buying, red=selling)
Powered by Fahodi Methodology. This is analytical output, not financial advice. Always do your own due diligence.  ·  Pipeline status  ·  Data: —